NCT06389799View on ClinicalTrials.gov

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Dedifferentiated Liposarcoma

Interventions

DRUG

Pemigatinib

selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet

DRUG

Retifanlimab

PD-1 inhibitor, Intravenous infusion

Trial Locations (4)

Unknown

RECRUITING

Oslo University Hospital HF, Oslo

RECRUITING

Sahlgrenska University Hospital, Gothenburg

RECRUITING

Skåne University Hospital, Lund

RECRUITING

Karolinska Universitetssjukhuset, Stockholm

All Listed Sponsors

lead

Lund University Hospital

OTHER

NCT06389799 - A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) | Biotech Hunter | Biotech Hunter